Based on the analysis on mRNA levels and reported studies on protein levels of various genes, Shvartsur et al. have constructed various schemes that illustrate the possible cross-talks between RKIP (active/inactive) and the identified gene products that underlie the mechanism of RKIP overexpression in multiple myeloma (MM). Clearly, such cross-talks would need to be experimentally validated in both MM cell lines and patient-derived tumor tissues. If validated, the differential molecular signatures between pre-MM and MM might lead to a more precise diagnosis/prognosis of the disease and disease stages and will also identify novel molecular therapeutic targets for pre-MM and MM.

Read the article

Read all reviews from JECCR

We are pleased to announce that a number of BioMed Central journals have come together to create a new cross-journal series on translational oncology.

Guest Edited by Prof Tommaso Dragani (Fondazione IRCCS Istituto Nazionale dei Tumori, Italy), the series is now accepting submissions of research articles that provide important developments in cancer research. Preclinical studies should provide a significant advance in knowledge, and have clear potential for strong clinical impact.

More information